Dynamics of fertility impairment and recovery after allogeneic haematopoietic stem cell transplantation in childhood and adolescence: results from a longitudinal study

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064203%3A_____%2F15%3A10294606" target="_blank" >RIV/00064203:_____/15:10294606 - isvavai.cz</a>

Výsledek na webu

<a href="http://dx.doi.org/10.1007/s00432-014-1781-5" target="_blank" >http://dx.doi.org/10.1007/s00432-014-1781-5</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1007/s00432-014-1781-5" target="_blank" >10.1007/s00432-014-1781-5</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Dynamics of fertility impairment and recovery after allogeneic haematopoietic stem cell transplantation in childhood and adolescence: results from a longitudinal study

Popis výsledku v původním jazyce

Fertility impairment and recovery after haematopoietic stem cell transplantation (HSCT) have been reported in both sexes, but little is known about how they develop over time. Our aim was to describe the dynamics of fertility impairment and recovery after HSCT. We retrieved treatment and fertility data for up to 12 years of 361 paediatric patients with malignant and non-malignant diseases from seven European centres. The patients had been treated with allogeneic HSCT between 2000 and 2005. Development of fertility impairment was observed in males (123/217, 56 %) after a median time of 2.6 years (range 0.1-11.4) and in females (82/144, 57 %) after 2.3 years (range 0.1-12.0) after HSCT. Different busulfan dosages had only a slight impact on the onset of fertility impairment (busulfan a parts per thousand yen16 mg/kg with a median time to fertility impairment of 2.9 vs. 3.9 years after busulfan < 14 mg/kg). Recovery from fertility impairment was observed in 17 participants after a median time of 4.1 years (range 1-10.6) in females (10/144, 7 %) and 2.0 years (range 1-6.3) in males (7/217, 3 %) after fertility impairment first appeared. In the light of the dynamics of fertility impairment and recovery in the HSCT patients reviewed, these patients should be counselled comprehensively regarding fertility preservation measures.

Název v anglickém jazyce

Dynamics of fertility impairment and recovery after allogeneic haematopoietic stem cell transplantation in childhood and adolescence: results from a longitudinal study

Popis výsledku anglicky

Fertility impairment and recovery after haematopoietic stem cell transplantation (HSCT) have been reported in both sexes, but little is known about how they develop over time. Our aim was to describe the dynamics of fertility impairment and recovery after HSCT. We retrieved treatment and fertility data for up to 12 years of 361 paediatric patients with malignant and non-malignant diseases from seven European centres. The patients had been treated with allogeneic HSCT between 2000 and 2005. Development of fertility impairment was observed in males (123/217, 56 %) after a median time of 2.6 years (range 0.1-11.4) and in females (82/144, 57 %) after 2.3 years (range 0.1-12.0) after HSCT. Different busulfan dosages had only a slight impact on the onset of fertility impairment (busulfan a parts per thousand yen16 mg/kg with a median time to fertility impairment of 2.9 vs. 3.9 years after busulfan < 14 mg/kg). Recovery from fertility impairment was observed in 17 participants after a median time of 4.1 years (range 1-10.6) in females (10/144, 7 %) and 2.0 years (range 1-6.3) in males (7/217, 3 %) after fertility impairment first appeared. In the light of the dynamics of fertility impairment and recovery in the HSCT patients reviewed, these patients should be counselled comprehensively regarding fertility preservation measures.

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FD - Onkologie a hematologie

OECD FORD obor

—

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2015

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Journal of Cancer Research and Clinical Oncology

ISSN

0171-5216

e-ISSN

—

Svazek periodika

141

Číslo periodika v rámci svazku

1

Stát vydavatele periodika

DE - Spolková republika Německo

Počet stran výsledku

8

Strana od-do

135-142

Kód UT WoS článku

000347289100016

EID výsledku v databázi Scopus

2-s2.0-84925032831